替格瑞洛在外周动脉疾病中血小板抑制作用优于氯吡格雷
研究纳入35例外周动脉疾病血运重建术后患者,用血栓弹力图血小板图比较阿司匹林-氯吡格雷与阿司匹林-替格瑞洛。替格瑞洛组ADP-最大振幅更低、血小板抑制率更高,氯吡格雷耐药率为34.6%。
要点
- 替格瑞洛较氯吡格雷显著降低ADP-最大振幅并提高血小板抑制率,提示更强血小板抑制。
- 氯吡格雷耐药率34.6%,支持部分PAD患者换用替格瑞洛的潜在获益。
- 研究样本小,出血与血栓事件数值仅作描述,不能据此判断临床结局优劣。
核心结论
- 在PAD血运重建术后患者中,替格瑞洛较氯吡格雷表现出更强的血小板抑制作用。
- 氯吡格雷耐药率较高,提示替格瑞洛对PAD患者可能有潜在临床获益。
研究设计与样本
- 单中心研究,纳入2022年12月至2024年12月接受血运重建手术的PAD患者。
- 共35例患者,平均年龄66.49±10.74岁,男性占65.7%。
- 在基线、1周、1月、3月、6月行血栓弹力图血小板图检测,比较由氯吡格雷换用替格瑞洛的患者。
- 部分患者行VerifyNow检测氯吡格雷耐药。
- 统计分析采用描述性统计和Wilcoxon配对检验比较TEG-PM参数。
主要发现
- 替格瑞洛组ADP介导的最大振幅显著低于氯吡格雷组(50.8 mm vs 59.5 mm,P < .0001)。
- 替格瑞洛组血小板抑制率显著高于氯吡格雷组(30.90% vs 13.40%,P = .0001)。
- 替格瑞洛组发生1例出血事件,氯吡格雷组记录到2例血栓事件。
- VerifyNow检测显示34.6%(26例中9例)患者对氯吡格雷耐药(P2Y12反应单位>180)。
关键数值与推荐
- 氯吡格雷耐药定义为VerifyNow P2Y12反应单位>180,本队列耐药率为34.6%(9/26)。
- 血小板抑制率:替格瑞洛30.90% vs 氯吡格雷13.40%,P = .0001。
- ADP-最大振幅:替格瑞洛50.8 mm vs 氯吡格雷59.5 mm,P < .0001。
临床怎么用
- 对PAD血运重建术后患者,可考虑用TEG-PM评估血小板抑制情况。
- 氯吡格雷耐药患者换用替格瑞洛可能获得更强血小板抑制。
- 替格瑞洛在PAD中尚无正式适应证,换药决策需结合出血风险个体化评估。
局限性
- 单中心小样本研究,仅35例,结果需更大样本验证。
- 出血与血栓事件为描述性观察,未做组间统计比较。
- 替格瑞洛目前缺乏PAD正式适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clopidogrel and ticagrelor are well-known antiplatelet drugs that inhibit P2Y12 receptors. Although clopidogrel is currently the standard of care for peripheral artery disease (PAD), 25% of patients are known to exhibit drug resistance due to genetic variability. Ticagrelor presents an alternative with reduced susceptibility to genetic variations and has demonstrated superior outcomes in acute coronary syndromes. However, ticagrelor currently lacks a formal indication for PAD management. This study aims to compare the clot strength and platelet function in patients with PAD transitioning from aspirin-clopidogrel to aspirin-ticagrelor using thromboelastography with platelet mapping (TEG-PM). METHODS: Patients with PAD who underwent revascularization surgery at a single tertiary center were enrolled from December 2022 to December 2024. TEG-PM analysis was performed at baseline, 1 week, 1 month, 3 months, and 6 months. Patients who switched from clopidogrel to ticagrelor were included in this study. Consenting patients also underwent VerifyNow testing for clopidogrel resistance. Statistical analysis used descriptive statistics and the Wilcoxon matched-pairs test to compare TEG-PM parameters. RESULTS: In our cohort of 35 patients (mean age 66.49 ± 10.74 years, 65.7% male), significant differences were observed in platelet function parameters. Adenosine diphosphate-mediated maximum amplitude that depicts clot strength was significantly lower with ticagrelor compared with clopidogrel (50.8 mm vs 59.5 mm, P < .0001). Ticagrelor also showed superior platelet inhibition (30.90% vs 13.40%, P = .0001). One bleeding event (defined as clinically significant hemorrhage that required medical intervention or transfusion) occurred on ticagrelor, whereas two thrombotic events (defined as arterial graft/stent occlusion or stenosis) were documented on clopidogrel. VerifyNow testing revealed that 34.6% of the patients (9 of 26) were resistant to clopidogrel (P2Y12 reaction units >180). CONCLUSIONS: Ticagrelor demonstrated superior platelet inhibition to clopidogrel in patients with PAD after revascularization. The high prevalence of clopidogrel resistance underscores the potential clinical benefit of ticagrelor for patients with PAD after revascularization.
引用
- Boya MN, Cieri IF, Rodriguez Alvarez AA, et al. Improved platelet inhibition with ticagrelor when compared to clopidogrel in peripheral artery disease patients. J Vasc Surg. 2025. PMID: 40850607. doi:10.1016/j.jvs.2025.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。